Alx Oncology Holdings (ALXO) Accumulated Depreciation (2019 - 2026)

Alx Oncology Holdings (ALXO) has 8 years of Accumulated Depreciation data on file, last reported at $2.1 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Depreciation fell 8.92% year-over-year to $2.1 million; the trailing twelve-month figure through Mar 2026 stood at $2.1 million (down 8.92% YoY), and the FY2025 full-year result was $2.0 million, down 4.72% from the prior year.
• Accumulated Depreciation rose to $2.1 million in Q1 2026, from $2.0 million in the prior quarter.
• In the past five years, Accumulated Depreciation ranged from a high of $2.3 million in Q1 2025 to a low of $121000.0 in Q1 2022.
• A 5-year average of $1.3 million and a median of $1.4 million in 2024 frame the typical range for Accumulated Depreciation.
• Across the five-year window, Accumulated Depreciation surged 669.23% in 2022 and decreased 8.92% in 2026, its largest moves.
• Tracing ALXO's Accumulated Depreciation over 5 years: stood at $403000.0 in 2022, then surged by 206.95% to $1.2 million in 2023, then surged by 67.91% to $2.1 million in 2024, then declined by 4.72% to $2.0 million in 2025, then advanced by 5.31% to $2.1 million in 2026.
• Business Quant data shows ALXO's Accumulated Depreciation at $2.1 million in Q1 2026, $2.0 million in Q4 2025, and $1.8 million in Q3 2025.